Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors

NCT06953089 is registered in ClinicalTrials.gov with DualityBio Inc. as lead sponsor.

NCT NCT06953089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06953089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors
Lead sponsor
DualityBio Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 18, 2025
Completion date
June 30, 2030
Enrollment
450 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors